JERUSALEM POST April 1st, 2018

A new Tel Aviv University study published in Nature Nanotechnology proposes a novel approach to manipulate genes using a self-assembling platform that delivers nucleic acids, such as small interfering RNAs (siRNAs), to distinct subsets of cells. While current practices of precision medicine target a single cellular receptor, the new modular platform offers a better biological approach that may hold the key to the future of personalized medicine, said Prof. Dan Peer of the laboratory of precision nanomedicine at the School of Molecular Cell Biology and Biotechnology, who led the research.

Read more

GEN News Highlights, February 2, 2018

Researchers at Tel Aviv University (TAU) lead by Dan Peer, Ph.D, have now developed a flexible, self-assembling small interfering RNA (siRNA) carrier platform that they claim can easily be customized to target any cell receptor. The technology, which doesn't rely on chemical conjugation, is based on a membrane-anchored lipoprotein, or linker (anchored secondary scFv enabling targeting, or ASSET), which is incorporated into siRNA-loaded lipid-based nanoparticles (LNPs), and which binds to the Fc region of antibodies.

In a report in Nature Nanotechnology, the mutidisciplinary TAU team, together with colleagues at Harvard Medical School and Integrated DNA Technologies, describe use of the platform to deliver cell-targeting siRNAs that improved disease symptoms in a mouse models of inflammatory bowel disease (IBD), and improved survival in a xenograft model of mantle cell lymphoma.

Read more

April 16, 2016

In this webinar, Professor Dan Peer will talk about how RNA-tLNPs can be utilized for therapeutic gene silencing in hematologcal B cell maligncies and as a tool to study leukocyte biology.

Precision Nanosystems Webinar

The Jerusalem Post - Israel News Jan, 1st, 2016

New research at Tel Aviv University offers significant hope of curing the most aggressive and presently incurable blood cancer called mantle cell lymphoma (MCL) and others like it. The promising and innovative system was found to successfully halt the proliferation of a cancer-related protein in white blood cells in both animal models and samples taken from MCL patients.

Read more

 Mouse model of MCL

Weinstein S. et al. Proc. Natl. Acad. Sci. USA 113(1) E16-E22, 2016.

Science Daily May 6, 2015

Some substances, when they undergo a process called 'rapid-freezing' or 'supercooling,' remain in liquid form - even at below-freezing temperatures. A new study is the first to break down the rules governing the complex process of crystallization through rapid-cooling. Its findings may revolutionize the delivery of drugs in the human body, providing a way to 'freeze' the drugs at an optimal time and location in the body.

Read more

START-UP ISRAEL (April 12, 2015)
The technique, developed by Prof. Dan Peer of TAU's Department of Department of Cell Research and Immunology and Scientific Director of TAU's Center for NanoMedicine, has proven itself in the past: It's based on the "cancer bullet" system Peer and other TAU researchers developed that delivers chemotherapy directly to cancer cells, using bioadhesive liposomes (BALs), consisting of regular liposomes reduced to nano-sized particles that attach themselves to the cancerous cells. Peer and Prof. Rimona Margalit, with whom he developed the method, have published several studies showing its effectiveness.

Read more


ISRAEL21c (March. 3, 2015)

New hope for tens of thousands diagnosed with gliomas as Tel Aviv University study shows potential way to stop brain tumor cell proliferation.

Professor Dan Peer and his colleages developed naoparticles-based treatment to target glioblastoma cells. Treatment involved injecting specially designed nanoparticles, which acted as the drug delivery system, into the tumors. The drug in this case was nucleic acid with interference RNAs, which attached to receptors that are expressed specifically on glioma cells, and stopped the activity of a key protein (gene) that regulates the rapid reproduction of the cancer cells.

Read more


New York, (Nov. 12, 2014)

An American Non-Profit, Marcella Rosen awards $10,000 (U.S.) Each to Israeli Inventors of a Cancer Bullet, a Metal Ligament Prosthesis, and a Bendable Plastic Touch Screen Display In First Annual Ceremony

Read more

Tel Aviv University, June, 2014

Ovarian cancer accounts for more deaths of American women than any other cancer of the female reproductive system.
Prof. Dan Peer has proposed a new strategy to tackle an aggressive subtype of ovarian cancer using a new nanoscale drug-delivery system designed to target specific cancer cells.

Nanomedicine for combat Ovarian Cancer, Read and Watch

June 3, 2014

Interview with Prof. Dan Peer  Read more

Professor Dan Peer appointed to Young Academy of Science

Tel Aviv Univeresity (May 14, 2014)

Tel Aviv Univesity's Prof. Dan Peer, of the The Department of Cell Research and Immunology of the George S. Wise Faculty of Life Sciences has been selected to take part in Israel's Young Academy of Science. The organization was established by the Israel Academy of Sciences and Humanities and consists of young scholars in the humanities, social sciences and natural sciences. Read more

TAU Researchers Devise Nano Mechanism to Combat Ovarian Cancer

Tel-Aviv university (Feb, 24, 2014)

Prof. Dan Peer of Tel Aviv University's Department of Cell Research and Immunology has proposed a new strategy to tackle an aggressive subtype of ovarian cancer using a new nanoscale drug-delivery system designed to target specific cancer cells. He and his team — Keren Cohen and Rafi Emmanuel from Peer's Laboratory of Nanomedicine and Einat Kisin-Finfer and Doron Shabbat, from TAU's Department of Chemistry — have devised a cluster of nanoparticles called gagomers, made of fats and coated with a kind of polysugar. When filled with chemotherapy drugs, these clusters accumulate in tumors, producing dramatically therapeutic benefits. Read more

Dan Peer580